The immune checkpoint inhibitor Tecentriq (atezolizumab) met its primary endpoint of disease-free survival in a Phase 3 study in people with early non-small cell lung cancer, Roche announced on 22 March. The interim analysis showed the drug improved outcomes as an adjuvant therapy following surgery and chemotherapy. At the time of the analysis, data on overall survival were immature.
